Form 4: Aethlon Medical Director Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director Chetan Shah was granted 21,815 restricted stock units in Aethlon Medical, vesting quarterly through March 2027.
Summary
- Director Chetan Shah acquired 21,815 shares of Aethlon Medical (AEMD) common stock via a restricted stock unit (RSU) grant.
- The transaction occurred on April 17, 2026, at a valuation of $2.29 per share.
- Following this grant, the director's total direct beneficial ownership increased to 23,021 shares.
- The RSUs are subject to a vesting schedule consisting of four equal quarterly installments starting June 30, 2026, and concluding March 31, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation rather than a change in company fundamentals or market outlook.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- The grant indicates continued commitment from the director to the company's long-term service.
Negatives
- The issuance of RSUs results in minor dilution to existing shareholders.
Risks
- Vesting is contingent upon the director's continued service with the company, creating a dependency on personnel retention.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of a director.
Management Comments
- No direct management commentary was provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members are incentivized to drive long-term shareholder value.
Comparison to Industry Standards
- The use of quarterly vesting schedules over a one-year period is consistent with standard equity compensation practices for non-employee directors in small-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 21,815 RSUs to Director Chetan Shah. | 04/17/2026 | Increases director equity stake, aligning interests with shareholders. |
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of the first tranche of RSUs on June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 04/17/2026 | Date of the RSU grant transaction. |
| 04/21/2026 | Date the Form 4 was signed and filed. |
| 06/30/2026 | First vesting date for the RSU grant. |
| 03/31/2027 | Final vesting date for the RSU grant. |
Keywords
Aethlon Medical, AEMD, Form 4, Insider Trading, Director Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.